LRRK2 rs34637584: What Your Genotype Means
The rs34637584 variant, commonly known as the G2019S mutation in the LRRK2 gene, is a well-studied genetic factor associated with an increased risk of developing late-onset Parkinson disease. While it is the most common genetic cause of monogenic Parkinson disease, its presence does not guarantee the development of the condition.
What each genotype means
Typical LRRK2 profile
This genotype represents the common, non-variant form of the LRRK2 gene at this position. It is not associated with the increased risk of Parkinson's disease linked to the G2019S mutation. Most individuals in the general population carry this genotype.
This is the most common genotype found in the vast majority of the global population.
Increased Parkinson's risk
This genotype indicates you carry one copy of the G2019S mutation, which is a known genetic risk factor for late-onset Parkinson's disease. This condition exhibits incomplete penetrance, meaning that carrying the mutation does not guarantee the development of the disease. You should discuss your family history and any concerns with a neurologist or genetic counselor.
Carried by approximately 0.1% of the global population, though frequencies are significantly higher in specific groups, such as Ashkenazi Jewish and North African Berber populations.
Elevated Parkinson's risk
This genotype indicates you carry two copies of the G2019S mutation. Research suggests this variant is associated with an increased lifetime risk of developing late-onset Parkinson's disease. Because this condition is complex and influenced by other genetic and environmental factors, you should consult with a medical professional for personalized health guidance.
This homozygous genotype is extremely rare in the general population, occurring primarily in populations with high carrier frequencies.
Understanding the Variant
The variant rs34637584, frequently referred to in scientific literature as G2019S, is a single nucleotide polymorphism located within the LRRK2 gene. Specifically, this missense mutation occurs in the kinase domain of the LRRK2 protein. A missense mutation means that the change in the DNA sequence results in the substitution of one amino acid for another in the final protein product. In this case, the substitution of glycine with serine at position 2019 is thought to alter the enzymatic activity of the protein. Because LRRK2 functions as both a kinase and a GTPase, this change is believed to result in a gain-of-function effect, where the protein becomes hyperactive. This hyperactivity is a central focus of research into how the variant contributes to the neurodegenerative processes observed in Parkinson disease.
The Role of the LRRK2 Gene
The LRRK2 gene, also known as PARK8, provides instructions for making a large, complex protein called leucine-rich repeat kinase 2. This protein is found in many tissues throughout the body, including the brain, where it plays a role in regulating the function of Rab proteins, which are involved in intracellular transport and membrane trafficking. When the LRRK2 protein is functioning normally, it helps maintain the health of neurons. However, when the G2019S mutation is present, the resulting protein exhibits increased kinase activity. This gain-of-function is hypothesized to disrupt normal cellular processes, potentially leading to the accumulation of toxic proteins or the dysfunction of cellular components that are critical for neuronal survival. Research continues to explore how this specific molecular change leads to the motor symptoms characteristic of Parkinson disease.
Research and Evidence Strength
The association between the LRRK2 G2019S variant and Parkinson disease is well-documented, though the evidence regarding its clinical impact is nuanced. It is considered the most common genetic determinant of Parkinson disease identified to date. However, the penetrance—the likelihood that a carrier will actually develop the disease—is incomplete and age-dependent. Studies have estimated that the cumulative incidence of Parkinson disease in carriers can be high by age 70, but it is not 100%. Furthermore, researchers have noted that other genetic factors, such as polygenic risk scores, may influence whether or not a carrier develops symptoms. Because the disease progression and clinical presentation can vary even among individuals with the same genotype, the evidence is categorized as having limited predictive power for an individual's specific clinical outcome.
Population Frequency
The prevalence of the rs34637584 variant is highly variable depending on ancestral background, reflecting historical founder events. Globally, the variant is relatively rare, with an estimated frequency of approximately 0.1%. However, this frequency is significantly higher in specific populations. For example, in the Ashkenazi Jewish population, carrier rates can reach 1-2%, and in some North African Berber populations, the frequency has been reported to be as high as 30%. These elevated frequencies are attributed to the dispersion of descendants from original founders who carried the mutation. Because of this uneven distribution, the clinical relevance of testing for this variant is often considered in the context of a person's family history and ethnic background, rather than as a universal screening tool.
What This Information Means for You
If you are aware of your status regarding the rs34637584 variant, it is important to understand that this is a risk factor, not a diagnostic tool. Carrying the variant does not mean you will definitely develop Parkinson disease, and not carrying it does not eliminate the risk of developing the condition, as most cases are idiopathic. This information should never be used to self-diagnose or make medical decisions. If you have concerns about your neurological health or family history, the most appropriate step is to consult with a neurologist or a genetic counselor. They can provide context based on your personal health history and discuss whether clinical screening or monitoring is appropriate. Always discuss any health-related genetic findings with a qualified healthcare professional who can interpret the results within the context of your overall health.
How common is this variant?
The variant is found in approximately 0.1% of the global population, but reaches up to 1-2% in Ashkenazi Jewish populations and ~30% in North African Berber populations.
Frequently asked questions
Does having the LRRK2 G2019S mutation mean I will get Parkinson disease?
No, having the mutation does not guarantee you will develop Parkinson disease. The penetrance is incomplete, meaning many carriers do not develop the disease, and those who do may have different ages of onset.
Is there a cure for LRRK2-related Parkinson disease?
Currently, there is no cure for Parkinson disease, including the form associated with LRRK2. Research is ongoing into LRRK2 inhibitors as potential therapeutic targets for early-stage disease.
Should I get tested for the LRRK2 G2019S variant?
Genetic testing for this variant is typically discussed with a neurologist or genetic counselor, especially if there is a strong family history of Parkinson disease. It is not recommended for the general population without clinical guidance.
How does the G2019S mutation affect the LRRK2 protein?
The G2019S mutation is a gain-of-function change that increases the kinase activity of the LRRK2 protein. This hyperactivity is believed to disrupt normal cellular functions in neurons.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs34637584?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29